Eledon Pharmaceuticals Inc (ELDN) 13F Filing Data & Analysis (Q2 2026)

ELDN ranks #3521 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

161 institutions disclose a position in ELDN, but none treat it as a major bet — even 22nw, LP, its most concentrated holder, allocates just 2.4% of its own portfolio to it.

Bvf Inc/il has added to its ELDN position for two straight quarters, increasing it by $15.3M to reach $24.8M today.

ELDN is down 0.7% today, but institutions show net buying of $31.4M this quarter — a divergence between today's price move and the underlying institutional flow.

ELDN reported a net loss of $45.6M in its latest fiscal year.

• Not yet profitable — net loss of $45.6M in the latest fiscal year
• Net income declined year over year, from -$36.2M to -$45.6M
• Operating cash flow was negative, using $62.3M in cash
• Current ratio of 7.40x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.40x equity — within a conventional range